DE69601345T2 - Propiophenon-Derivate und Verfahren zur ihrer Herstellung - Google Patents

Propiophenon-Derivate und Verfahren zur ihrer Herstellung

Info

Publication number
DE69601345T2
DE69601345T2 DE69601345T DE69601345T DE69601345T2 DE 69601345 T2 DE69601345 T2 DE 69601345T2 DE 69601345 T DE69601345 T DE 69601345T DE 69601345 T DE69601345 T DE 69601345T DE 69601345 T2 DE69601345 T2 DE 69601345T2
Authority
DE
Germany
Prior art keywords
preparation
hydrogen atom
propiophenone derivatives
propiophenone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69601345T
Other languages
English (en)
Other versions
DE69601345D1 (de
Inventor
Kenji Tsujihara
Kunio Saito
Mitsuya Hongu
Mamoru Matsumoto
Kozo Doeru Shugakuin Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of DE69601345D1 publication Critical patent/DE69601345D1/de
Publication of DE69601345T2 publication Critical patent/DE69601345T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69601345T 1995-11-07 1996-10-24 Propiophenon-Derivate und Verfahren zur ihrer Herstellung Expired - Lifetime DE69601345T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7288487A JP3059088B2 (ja) 1995-11-07 1995-11-07 プロピオフェノン誘導体およびその製法

Publications (2)

Publication Number Publication Date
DE69601345D1 DE69601345D1 (de) 1999-02-25
DE69601345T2 true DE69601345T2 (de) 1999-06-17

Family

ID=17730854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69601345T Expired - Lifetime DE69601345T2 (de) 1995-11-07 1996-10-24 Propiophenon-Derivate und Verfahren zur ihrer Herstellung

Country Status (12)

Country Link
US (1) US5767094A (de)
EP (1) EP0773226B1 (de)
JP (1) JP3059088B2 (de)
KR (1) KR100333572B1 (de)
CN (1) CN1049222C (de)
AT (1) ATE175676T1 (de)
CA (1) CA2189603C (de)
DE (1) DE69601345T2 (de)
DK (1) DK0773226T3 (de)
ES (1) ES2128137T3 (de)
SG (1) SG40895A1 (de)
TW (1) TW460477B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176600T3 (es) * 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
AU5755200A (en) 1999-08-27 2001-03-26 Joel R.L. Ehrenkranz Method of using dihydrochalcone derivatives to block glucose transfer
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CN100384430C (zh) * 2001-04-04 2008-04-30 奥索-麦克尼尔药品公司 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗
CA2442917C (en) * 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
EP1679966A4 (de) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv Substituierte benzimidazol-, benzotriazol- und benzimidazolon-o-glukoside
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
AR048376A1 (es) * 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv C- glicosidos heterociclos fusionados sustituidos
DK2896397T4 (da) * 2003-08-01 2020-11-16 Mitsubishi Tanabe Pharma Corp Nye forbindelser med hæmmende aktivitet mod natriumafhængig glukosetransportør
EA010655B1 (ru) * 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
US7129220B2 (en) * 2003-08-01 2006-10-31 Janssen Pharmaceutica N.V Substituted indole-O-glucosides
FR2862303B1 (fr) * 2003-11-17 2006-01-06 Agronomique Inst Nat Rech Preparations colorantes hydrosolubles jaunes derivees des dihydrochalcones, leur procede des preparation, et leurs utilisations
TWI332707B (en) 2005-08-04 2010-11-01 Au Optronics Corp Array substrate of a liquid crystal display and method of fabricating the same
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2647504T3 (es) * 2007-09-10 2017-12-21 Janssen Pharmaceutica N.V. Proceso para la preparación de compuestos útiles como inhibidores de SGLT
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN102105153B (zh) 2008-05-22 2014-03-05 百时美施贵宝公司 Sglt2抑制剂的医药用途和含该抑制剂的组合物
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
CN102648196B (zh) * 2009-10-14 2016-04-27 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (de) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systeme und verfahren zur verwaltung von prädiabetes mit einer pharmazeutischen gliflozin-natrium-glucose-cotransport-2-inhibitorzusammensetzung
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same

Also Published As

Publication number Publication date
MX9605415A (es) 1997-10-31
EP0773226A1 (de) 1997-05-14
ATE175676T1 (de) 1999-01-15
CN1049222C (zh) 2000-02-09
CA2189603A1 (en) 1997-05-08
SG40895A1 (en) 1997-06-14
DE69601345D1 (de) 1999-02-25
TW460477B (en) 2001-10-21
JPH09124686A (ja) 1997-05-13
US5767094A (en) 1998-06-16
KR970027098A (ko) 1997-06-24
CA2189603C (en) 2003-06-10
EP0773226B1 (de) 1999-01-13
ES2128137T3 (es) 1999-05-01
JP3059088B2 (ja) 2000-07-04
CN1151405A (zh) 1997-06-11
DK0773226T3 (da) 1999-08-30
KR100333572B1 (ko) 2002-09-18

Similar Documents

Publication Publication Date Title
DE69601345D1 (de) Propiophenon-Derivate und Verfahren zur ihrer Herstellung
HU9600834D0 (en) Quinazoline derivatives
CA2183655A1 (en) 4-polycyclic amino-substituted quinazoline derivatives
AU5752194A (en) Benzimidazole compounds, their use and preparation
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
MY119350A (en) Propiophenone derivatives and process for preparing the same
DE69508463T2 (de) Propiophenonderivate und Verfahren zu deren Herstellung
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
ATE207749T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung von atherosklerose und ischämischer herzerkrankungen
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
HUT50354A (en) Process for producing new s-adenosylmethionine decarboxilase inhibitors
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
DE3767533D1 (de) D-nor-7-ergolinderivate, verfahren zu ihrer herstellung, pharmazeutische zubereitung und verwendung.
DE69626301T2 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
ATE181331T1 (de) Salmycine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU1370895A (en) 2'-deoxy-5-fluorouridine derivative, pharmaceutically acceptable salt thereof, process for producing the same, and antitumor drug
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition